AbCellera Biologics Inc vs Domino's Pizza, Inc. — how do they compare? AbCellera Biologics Inc trades at $9.14 (market cap $2.99B), while Domino's Pizza, Inc. trades at $355.78 (market cap $11.82B). The key difference: Domino's Pizza, Inc. is far larger — about 4× AbCellera Biologics Inc's market cap, and Domino's Pizza, Inc. pays a 2.23% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DPZ | |
|---|---|---|
Market Cap | $2.99B | $11.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $467.30 |
52-Week Low | $2.78 | $282.89 |
Enterprise Value | $2.58B | $16.78B |
Dividend Yield | — | 2.23% |
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →